Nebenwirkungen · Riximyo
Riximyo 100 mg concentrate for solution for infusion Riximyo 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21
HOS-141035 · Präparat HOS-098602
Neurologic disorders During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2%) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle. There was no difference between the treatment groups in the incidence of other thromboembolic events. In contrast, three patients (1.5%) had cerebrovascular events in the CHOP group, all of which occurred during the follow-up period. In CLL, the overall incidence of grade 3 or 4 nervous system disorders was low both in the first-line study (4% R-FC, 4% FC) and in the relapsed/refractory study (3% R-FC, 3% FC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-04T16:41:00Z · SHA-256 4fe21e50fef50537643123868d3f044762b7d55eab7d50a56c1d469305291ee4 · Passage b1508f7f33a2ca2dc812f3923e1c11ce0257d645167eacd95a9f96d3d48dd42d · Zeichen 20989–21691 im Abschnitt